What Happened

Larimar Therapeutics submitted the first module of a rolling Biologics License Application (BLA) to the FDA for nomlabofusp, targeting accelerated approval for Friedreich’s ataxia (FA). The submission follows positive Type B pre-BLA meeting feedback and new open-label data showing sustained clinical improvements and biomarker responses over 800 days of treatment.

Who Is Affected

This impacts FA patients (ages 2+), particularly the 49% non-ambulatory participants in the study. Neurologists and rare disease specialists treating FA now have a potential disease-modifying therapy in late-stage development. Competitors developing FA treatments face accelerated timeline pressure.

Market Impact

• First potential disease-modifying therapy for FA, a fatal condition with no approved root-cause treatments
• FDA accepted skin frataxin as a novel surrogate endpoint, setting precedent for biomarker-driven approvals
• Phase 3 confirmatory study enrollment underway, creating near-term engagement opportunities

What to Watch

Monitor remaining BLA module submissions in H2 2026 and FDA review timeline. The expanded pediatric trial (ages 2-11) represents an untreated population. Commercial readiness activities will accelerate if accelerated approval is granted.